MRKR · NASDAQ · Biotechnology

Marker Therapeutics (MRKR)

Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.

$1.25
After hours+0.03 (+2.46%)
At close$1.22(+1.67%)